Study of EZN-2208 Pediatric Patients With Solid Tumors

Stopped early · Phase 1/Phase 2

Conditions studied: Solid Tumors

In brief

The goal of this clinical research study is to find the highest tolerable dose of EZN-2208 that can be given to pediatric patients with Relapsed or Refractory Solid Tumors. The safety of the study drug and its effect on the disease will also be studied.

Key facts

Study ID

NCT01295697

Run by

Enzon Pharmaceuticals, Inc.

People needed

32

Starts

2010-02-01

Expected to finish

2013-01-01

Last updated by the study team

2022-02-14

Who can join

Age: 1 and older, up to 21. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with histologic verification of malignancy at original diagnosis or relapse.
• Measurable or evaluable disease
• Karnofsky score more or equal to 50 for patients >16 years of age and Lansky score more or equal to 50 for patients <16 years of age
• Patients previously treated with irinotecan will be eligible for this study if they have not had documented progressive disease during treatment with an irinotecan-containing regimen.
• Adequate hematologic, hepatic, coagulation, renal, and metabolic function

You may not qualify if…

• Pregnant or breast feeding patients will not be enrolled in this study
• Patients who are currently receiving other anticancer agents
• Patients who have an uncontrolled infection
• Patients requiring cytochrome P450 3A4 enzyme inducing or inhibiting agents

Where it is running

• Lia Gore, MD — Aurora, Colorado, United States
• Suzanne Shusterman, MD — Boston, Massachusetts, United States
• Rochelle Bagatell, MD (Principal Investigator) — Philadelphia, Pennsylvania, United States
• Jodi Muscal, MD — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.